EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive value of [99mTc]Tc-MAA SPECT/CT personalised dosimetry in 90Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study

Grace Keane, J Chalaye, B Guiu, L Tselikas, K D Fowers, E Boucher, E Garin, X Palard, M G E H Lam

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8217-8228

DOI: 10.1007/s00259-026-08079-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 11.08.2026. Verfasst von Grace Keane und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, University Medical Center, Utrecht, 3508 GA, The Netherlands. g.e.m.keane@umcutrecht.nl. Hauptthemen laut MEDLINE: Liver Neoplasms, Radioembolization, Therapeutic, Yttrium Radioisotopes, Carcinoma, Hepatocellular. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The DOSISPHERE-01 study demonstrated a survival benefit for patients treated with 90 Y radioembolization using personalised [ 99m Tc]Tc-MAA guided versus standard dosimetry guided treatment. This ancillary analysis complements DOSISPHERE-01 by reporting post-treatment dosimetry and assessing agreement between predictive ([ 99m Tc]Tc-MAA) and post-treatment ( 90 Y) absorbed doses. Materials and methods All DOSISPHERE-01 patients with both pre-treatment [ 99m Tc]Tc-MAA SPECT/CT and post-treatment 90 Y imaging were eligible. Multicompartment dosimetry was performed using two segmentation methods: anatomic (MRI/CT) and count-threshold based (SPECT). Mean normal liver tissue and index-lesion absorbed dose, and dose volume histogram (DVH) metrics were determined using Simplicit 90 Y (Mirada Medical, Oxford UK). Agreement between [ 99m Tc]Tc-MAA and 90 Y absorbed doses was assessed via Bland-Altman and paired-sample analysis, with correlation assessed via linear-regression.

Results

Thirty-seven patients were included: 19 from the personalised arm and 18 from the standard dosimetry arm. Pre- and post-treatment absorbed dose differences were not statistically significant for the index lesion (241 Gy vs. 229 Gy, p = 0.15; mean difference 11.9 Gy; 95% LoA − 84.3 to 108.2 Gy), Perfused Volume Normal Liver Tissue (PVNT) (91 Gy vs. 99 Gy, p = 0.14; mean difference − 8.2 Gy; 95% LoA − 71.6 to 55.1 Gy), or DVH metrics (V200, D70, D50) using anatomic segmentation. Corresponding metrics were significantly different using count-threshold segmentation ( p < 0.05). For both methods, pre- and post-treatment mean index lesion and PVNT absorbed doses, and V200, D70, D50 were strongly correlated (Pearsons Correlation Coefficient > 0.65, p < 0.05).

Conclusion

90 Y absorbed dose outcomes in the DOSISPHERE-01 study corresponded closely with [ 99m Tc]Tc-MAA predictive dosimetry, confirming the validity of [ 99m Tc]Tc-MAA for dosimetry-based treatment planning in this clinical scenario. Agreement was maximised using anatomic segmentation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsRadioembolization, TherapeuticYttrium RadioisotopesCarcinoma, HepatocellularSingle Photon Emission Computed Tomography Computed TomographyTechnetium Tc 99m Aggregated AlbuminPrecision MedicineHumansMaleFemaleRadiometryAgedMiddle AgedPredictive Value of Tests

Stichwörter der Autor:innen

Hepatocellular CarcinomaPET/CTRadioembolizationSPECT/CTTechnetium-99m macroaggregated albuminYttrium-90

Substanzen

Yttrium RadioisotopesYttrium-90Technetium Tc 99m Aggregated Albumin

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, University Medical Center, Utrecht, 3508 GA, The Netherlands. g.e.m.keane@umcutrecht.nl.
  • Boston Scientific Corporation, Marlborough, MA, USA. g.e.m.keane@umcutrecht.nl.
  • Assistance Publique Hôpitaux de Paris, Paris, France.
  • Department of Radiology, St-Eloi University Hospital, Montpellier, France.
  • Département d'Anesthésie Chirurgie et Interventionnel, Interventional Radiology unit, Gustave Roussy Université Paris Saclay, Villejuif, France.
  • Boston Scientific Corporation, Marlborough, MA, USA.

Zitieren

APA

Keane, G., Chalaye, J., Guiu, B., Tselikas, L., Fowers, K. D., Boucher, E., Garin, E., Palard, X., & Lam, M. G. E. H. (2026). Predictive value of [99mTc]Tc-MAA SPECT/CT personalised dosimetry in 90Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8217-8228. https://doi.org/10.1007/s00259-026-08079-8

Vancouver

Keane G, Chalaye J, Guiu B, Tselikas L, Fowers KD, Boucher E, et al. Predictive value of [99mTc]Tc-MAA SPECT/CT personalised dosimetry in 90Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8217-8228. doi:10.1007/s00259-026-08079-8

BibTeX
@article{Keane2026,
  author = {Keane, Grace and Chalaye, J and Guiu, B and Tselikas, L and Fowers, K D and Boucher, E and Garin, E and Palard, X and Lam, M G E H},
  title = {Predictive value of [99mTc]Tc-MAA SPECT/CT personalised dosimetry in 90Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8217--8228},
  doi = {10.1007/s00259-026-08079-8}
}
Kostenlos starten →